• Agreement enables Mayo Clinic to resell and distribute EchoSolv HF following FDA clearance
• EchoSolv HF to be deployed via Mayo Clinic Platform - Solutions Studio Program
• Revised agreement includes improved commercial terms and automatic extension

Echo IQ Limited (ASX: EIQ) has expanded its agreement with the Mayo Foundation for Medical Education and Research ('Mayo'), a legal, non-profit entity of the Mayo Clinic, to resell and distribute the Company's heart failure clinical decision support solution ('EchoSolv HF') following clearance from the US Food & Drug Administration ('FDA'). Under the agreement, EchoSolv HF will be offered through the Mayo Clinic Platform ('MCP') - Solutions Studio Program to Mayo Clinic Hospitals, Mayo Clinic Health System Network and non-Mayo Clinic hospitals utilizing the MCP Solutions Studio Program following receipt of FDA clearance. The revised agreement strengthens the commercial framework between the parties and supports the planned deployment of EchoSolv HF within the Mayo Clinic Platform. The expanded agreement follows a validation study conducted through the Mayo Clinic Platform validation program, which met its primary endpoint. The Company has lodged its market clearance application for EchoSolv HF with the FDA via the 510(k) premarket notification pathway and is currently progressing through the FDA review process. Clearance has the potential to unlock a significant market opportunity for Echo IQ, as heart failure represents a substantial and growing burden on the US healthcare system.

Following receipt of FDA clearance, Echo IQ is positioned to deploy EchoSolv HF via the Mayo Clinic Platform, providing potential access to a high-volume clinical network and established distribution pathway.

The expanded agreement with Mayo Clinic represents a key step in Echo IQ's strategy of converting clinical validation into potentially revenue-generating installations, while also supporting broader adoption across additional hospital networks and platform participants.